Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
A study in this month’s issue of The American Journal of Managed Care® (AJMC®) was mentioned by POLITICO in their Morning eHealth on Monday. The study, “Medicare Annual Wellness Visit Association With Health Quality and Costs,” found that among beneficiaries treated by primary care providers affiliated with 2 accountable care organizations, the Medicare Annual Wellness Visit was associated with greater delivery of preventive care and lower total healthcare costs.
An article from the Journal of Clinical Pathways cited an AJMC® interview with Kathleen Lokay, president and chief executive officer of Via Oncology. During the interview, Lokay discussed how clinical pathways can help providers avoid delays with prior authorization by ensuring that all the necessary information is there.
OBR Oncology’s Tuesday daily newsfeed included an article from AJMC®’s sister publication The Center for Biosimilars®. The article, “FDA Approves Pfizer’s Trastuzumab Biosimilar, Trazimera,” covered the FDA’s approval of the biosimilar referencing Herceptin based on data from REFLECTIONS B327-02. Wednesday’s newsfeed included AJMC®’s latest episode of Managed Care Cast. During the podcast, Ted Okon, executive director of the Community Oncology Alliance (COA), discusses a number of policies affecting COA’s members, including proposals around chimeric antigen receptor T-cell therapies.
An article from AJMC® on specialty drugs was included in the National Pharmaceutical Council’s Monday CER Daily Newsfeed. The article, “Specialty Drugs Remain a Costly Concern for Employers With No Easy Answers,” covered a report from the Pharmacy Benefit Management Institute that found costs remain the top concern of healthcare purchasers of pharmacy benefits. Wednesday’s newsfeed included the AJMC® article “New Statewide Pilot in Virginia Aims to Reduce Low-Value Care, Decrease Costs and Patient Harm,” which reported that the Virginia Center for Health Innovation is launching a 3-year statewide pilot to reduce the use of low-value care in the commonwealth. The newsfeed also included The Center for Biosimilars'® article “ICER Paper Analyzes 3 Options to Overhaul Pharmaceutical Rebates,” which covered a report from the Institute for Clinical and Economic Review (ICER) discussing possible alternatives to the pharmaceutical rebate systems that currently exists with pharmacy benefit managers.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen